The BINDAZYME™ Anti-Phosphatidylserine kit has recently been FDA cleared as an aid in the diagnosis of antiphospholipid syndrome (APS). Phosphatidylserine monitoring may be more effective at tracking APS than cardiolipin monitoring, as phosphatidylserine is more specific and physiologically relevant. The assay features ready-to-use and color-coded reagents, calibrators and controls, break-apart wells, three 30-minute incubations, and interchangeable common components.
The Binding Site
www.CLPmag.com